With the assistance of funds granted by Congress, the Department of Veteran Affairs (VA) will extend new hepatitis C (HCV) treatment to all infected veterans within their healthcare system, of all stages of illness and regardless of whether or not the infection had been acquired during military service.
The VA’s integrated healthcare system, the largest in the nation, is comprised of more than 1,700 hospitals, clinics, counseling centers, and other facilities that aim to offer quality care for all who have served for America. This decision is paramount when it comes to improved identification and treatment of what an article
published in JAMA
calls, “the nation’s deadliest infectious disease.” According to the Centers for Disease Control and Prevention (CDC), HCV-related deaths have reached an all-time high of 19,659 in 2014, and according to John W. Ward, MD, director of CDC’s Division of Viral Hepatitis, “Because hepatitis C often has few noticeable symptoms, the number of new cases is likely much higher than what is reported.”
The VA is doubling the number of patients who will be treated with HCV antiviral therapy since last year, as it begins to treat 1,100 patients a week. The VA aims to almost double this number as well by the end of the year to treating 2,000 patients per week, David Ross, MD, director of the VA’s HIV, hepatitis, and public health pathogens programs, reported. In addition to increased treatment, another primary focus of the VA is to screen veterans born 1945 and 1965 for the virus, due to the fact that people who were born within that time frame account for more than 75% of HCV infections, according to the JAMA
Five medical centers in San Francisco; Richmond, Virginia; Ann Arbor, Michigan; West Haven, Connecticut; and Portland, Oregon are at the forefront of the initiative as they focus on providing expert HCV advice as well as training throughout the healthcare system. The overall end goal is to “eradicate as much of the disease as we can,” according to Chester Good, MD, chair of the VA’s medical advisory panel for pharmacy benefits management and an internist at the VA Pittsburgh Healthcare System.
VA Faces Insuffient Funds
Lack of funds has been an ongoing obstacle for the VA when it comes to effectively treating veterans infected with HCV. Last year, the government agency started restricting treatment access to veterans who had advanced liver disease due to high demands for new HCV therapies, an elevated cost of medicine, and a budget that could not cover all of the needed expenses. These medications were effective in curing HCV; where previous therapies cured only half of the patients and took twice as long, these results showed that after a 12- or 24-week course of therapy, 95% of HCV cases had been eradicated with minimal adverse effects.
According to the article, 89,000 veterans have been diagnosed with HCV but have not yet received treatment. About 40,000 more may be infected with the virus but have not yet received the diagnosis. Taking those numbers into account, authors of the article estimate that the price of HCV drugs would come to around $12.9 billion, and even with a 46% discount, the total still comes to about $7 billion for treatment. However, due to a bigger budget provided by the Congress, the VA will be provided with $1.5 billion; $1 billion of which will be used to pay for treatment medications, allowing for more veterans to be treated. In order to treat 35,000 cases of veterans diagnosed with HCV, the VA will ask for a $1.5 billion budget for next year as well.